Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK, Synta in STA-4783 deal

GlaxoSmithKline (LSE:GSK; GSK) and SNTA partnered to develop and commercialize STA-4783, a small molecule

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE